Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
종목 코드 BJDX
회사 이름Bluejay Diagnostics Inc
상장일Nov 10, 2021
CEOMr. Neil (Indranil) Dey
직원 수7
유형Ordinary Share
회계 연도 종료Nov 10
주소360 Massachusetts Avenue, Suite 203
도시ACTON
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호01720
전화19786310152
웹사이트https://bluejaydx.com/
종목 코드 BJDX
상장일Nov 10, 2021
CEOMr. Neil (Indranil) Dey
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음